What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?

Autor: O. Chapet, Jean-Pierre Gerard, O. Bouche, J.-F. Bosset, F. Bonnetain, P. Maingon, N. Methy, L. Radosevic-Jelic, Laurent Mineur, Laurence Collette, T. Conroy, Gilles Calais

Publikováno v: European Journal of Cancer
European Journal of Cancer, Elsevier, 2012, epub ahead of print. 〈10.1016/j.ejca.2012.03.016〉
European Journal of Cancer, Elsevier, 2012, epub ahead of print. ⟨10.1016/j.ejca.2012.03.016⟩

International audience; BACKGROUND: Two phase III trials of neoadjuvant treatment in T3-4 rectal cancer established that adding chemotherapy (CRT) to radiotherapy (RT) improves pathological complete response (pCR) and local control (LC). We combined

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::126ae592e1bd1a12c7393b34b5d4195c
https://hal.archives-ouvertes.fr/hal-00719129

Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer

Autor: I, Popov, L, Radosevic-Jelic, S, Jezdic, M, Milovic, N, Borojevic, S, Stojanovic, V, Stankovic, T, Josifovski, I, Kezic

Publikováno v: Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 13(4)

To compare a bi-weekly infusion of leucovorin (LV) 5-fluorouracil (5-FU) for 2 days, plus oxaliplatin (LV5- FU2-oxaliplatin) and LV5-FU2-cisplatin (CDDP) regimens with respect to toxicity, objective response rates, time to progression (TTP) and overa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9e3ac793c08ff7af269c11c8522ea773
https://pubmed.ncbi.nlm.nih.gov/19145671

Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group

Autor: J F, Bosset, G, Calais, A, Daban, C, Berger, L, Radosevic-Jelic, P, Maingon, E, Bardet, M, Pierart, A, Briffaux

Publikováno v: European journal of cancer (Oxford, England : 1990). 40(2)

The European Organisation for Research and Treatment of Cancer (EORTC) 22921 four-arm randomised trial questioned the value of preoperative chemoradiation (XRT-CT) versus preoperative radiation (XRT) and the value of additional postoperative chemothe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::07e78d32b80fe70b7a58ea0c46bf098e
https://pubmed.ncbi.nlm.nih.gov/14728936

An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?

Autor: L. Radosevic-Jelic, L. Collette, O. Bouche, T. Conroy, J.F. Bosset, Gilles Calais, Olivier Chapet, F. Bonnetain, Philippe Maingon, Jean-Pierre Gerard, N. Methy, L. Mineur

Publikováno v: Journal of Clinical Oncology. 29:3506-3506

3506 Background: Phase III trials of preoperative chemoradiotherapy (CRT) in T3-4 rectal cancer have demonstrated the benefit of adding 5FU/leucovorin to radiotherapy (RT) on pathological complete ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::08f6f447e81d4d876462c75de9803962
https://doi.org/10.1200/jco.2011.29.15_suppl.3506

Absence of brain metastases in late relapse of HER2-overexpressed breast carcinoma

Autor: Z. M. Tomasevic, Jelena Spasic, Zorica Tomasevic, Ljiljana Stamatovic, L. Radosevic Jelic, D. Jovanovic, S. Jelic, Suzana Vasovic

Publikováno v: Journal of Clinical Oncology. 25:1014-1014

1014 Background: The incidence of brain metastases (BM) in HER2 3+ breast carcinoma (BC) reported in the literature is between 20–34%, usually during first 2 years of metastatic disease. However, there are limited data about BM as a late relapse in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f4b54aa5964a967d3e2f03aa07f0351a
https://doi.org/10.1200/jco.2007.25.18_suppl.1014